Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 Studied IBS: Mechanism vs Clinical Application Comparison

Mucosal Healing Accelerated healing in rodent colitis models, 40–60% reduction in inflammation scores within 7–14 days No controlled trials in IBS populations; case reports suggest subjective improvement but lack validation Strong mechanistic plausibility, wea

This comparison does not assign a generated winner or score.

  • Mucosal Healing
  • Accelerated healing in rodent colitis models, 40–60% reduction in inflammation scores within 7–14 days
  • No controlled trials in IBS populations; case reports suggest subjective improvement but lack validation
  • Strong mechanistic plausibility, weak clinical confirmation
  • Anti-Inflammatory Effect
  • Reduced TNF-alpha, IL-6, and myeloperoxidase in induced gut injury models
  • Not measured in IBS-specific trials; inflammatory markers not consistently elevated in all IBS subtypes
  • Relevant for post-infectious or inflammatory IBS subtypes, less so for purely motility-driven IBS
  • Visceral Pain Modulation
  • Some evidence of reduced nociceptive signalling in rodent pain models
  • No human data on visceral hypersensitivity or pain thresholds in IBS patients
  • Theoretical benefit, no clinical validation
  • Gut Barrier Function
  • Improved tight junction integrity in Caco-2 cell monolayers and rodent permeability models
  • Not assessed in human IBS trials; relevance depends on whether permeability is a primary driver in individual patients
  • Potentially useful in leaky gut subtypes, not generalisable to all IBS
  • Administration Route
  • Effective via subcutaneous, oral, and intraperitoneal routes in animal studies
  • Human case reports primarily use subcutaneous; oral bioavailability in humans not well-characterised
  • Route selection remains empirical without pharmacokinetic data
  • Safety Profile
  • No significant adverse events in rodent toxicity studies up to 100x therapeutic dose
  • Human safety data limited to small case series; no long-term follow-up or large cohort safety trials
  • Appears well-tolerated short-term, but long-term safety unknown
More references

Related material